期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 14, 期 2, 页码 120-129出版社
WILEY
DOI: 10.1093/eurjhf/hfr173
关键词
Energetics; Cardiac metabolism; AMP-activated kinase; Heart failure
资金
- National Institutes of Health [K02 HL107448, R01 HL087149, R01 HL104181, 1PO1 HL108795, PO1-HL074237-06, K12-HL083790]
- Pfizer
- Novartis
- Amgen
- Roche
- Otsuka
- Sigma Tau
- Merck
- Scios
- National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish
The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据